Streetbeat News

Stock Prices

PACB

Pacific Biosciences (NASDAQ:PACB) has been analyzed by 10 analysts, showing a shift towards a more cautious outlook with recent ratings leaning towards neutral. The average 12-month price target has been significantly lowered from $8.90 to $4.4, reflecting a 50.56% decline and indicating a bearish sentiment. Analysts from firms like Piper Sandler, Barclays, and Goldman Sachs have adjusted their price targets downwards in response to market dynamics and company performance. Despite positive revenue growth of 113.35% as of December 31, 2023, Pacific Biosciences faces challenges in profitability and efficient capital utilization, with a net margin of -140.55% and ROE of -11.2%.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:00 pm

OVV

Analysts have mixed views on Ovintiv (NYSE:OVV), with 12 ratings over the last three months showing a range from bullish to indifferent. The average 12-month price target is $58.83, marking a 10.81% increase from the previous target. Recent analyst actions include ratings and price target adjustments, reflecting changing market conditions and company performance. Ovintiv's financial health shows a negative revenue trend with a -7.8% growth, but strong profitability indicators like a net margin of 14.37% and ROE of 3.28%.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:00 pm

MRNA

Moderna (NASDAQ:MRNA) has significantly outperformed the market over the past 5 years, with an annualized return of 27.7% and an average annual return of 40.43%, growing a $100 investment to $537.32. The company now has a market capitalization of $45.61 billion.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:00 pm

RRC

Range Resources (NYSE:RRC) has been the subject of 24 analyst evaluations over the last three months, showing a diverse range of opinions. The average 12-month price target for RRC has been raised to $37.21, reflecting a 4.96% increase from the previous target of $35.45. Analysts have adjusted their ratings and price targets, indicating a generally positive outlook on the company's performance. Range Resources, focusing on Marcellus Shale in Pennsylvania, has shown strong financial health despite a decline in revenue growth and operates with a lower market capitalization compared to industry peers.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:00 pm

WPM

Wheaton Precious Metals (NYSE:WPM) has outperformed the market with an annualized return of 22.05% over the past 5 years, growing a $1000 investment to $2,732.53. The company's market capitalization stands at $24.64 billion.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:00 pm

FDX

FedEx's (NYSE:FDX) short interest has increased by 20.39% since the last report, with 4.14 million shares sold short, representing 1.83% of its float. This indicates a bearish market sentiment, although it has less short interest compared to its peers' average of 3.98%.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:00 pm

HSY

Hershey's (NYSE:HSY) short interest has decreased by 5.85%, with 3.98 million shares sold short, representing 3.06% of its float. The current short interest suggests a bullish sentiment as it is lower than the peer group average of 4.17%. Short interest is a key indicator of market sentiment, and a decrease often signals that investors are becoming more optimistic about the stock.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:00 pm

LHX

L3Harris Technologies (NYSE:LHX) has seen a decrease in short interest, now at 1.07% of its float, down 6.96% from the last report. With 1.81 million shares sold short, it would take about 1.55 days to cover all short positions. This decline in short interest could indicate a more bullish sentiment towards LHX compared to its peers, where the average short interest as a percentage of float is 2.46%.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 6:00 pm

INKT

MiNK Therapeutics, Inc. (NASDAQ:INKT) shares surged 11% after announcing a $5.8 million private placement financing to accelerate clinical trials of its leading therapy, MiNK-215. The company plans to sell 4.64 million shares at $1.25 each, a 25% premium to current prices, with the financing aimed at advancing MiNK-215's clinical trials targeting solid tumors. The PIPE deal is expected to close on May 14, 2024. Additionally, MiNK announced the appointment of Yekaterina Chudnovsky as Board Observer.

Portfolio Pulse from Dylan Berman

May 13, 2024 | 5:48 pm

GME

KWEB

PGJ

TLT

TME

Tech stocks saw a slight increase ahead of key inflation data, with GameStop experiencing a significant surge due to social media activity. The S&P 500 remained stable, while the Nasdaq 100 and Russell 2000 posted gains. Treasury yields dipped slightly, benefiting the iShares 20+ Year Treasury Bond ETF. Meme stocks rallied, notably GameStop, driven by 'Roaring Kitty's' return. Tencent's revenue beat spurred a rally in Chinese stocks, positively impacting related ETFs. The commodities market saw mixed movements, with oil up and gold down.

Portfolio Pulse from Piero Cingari

May 13, 2024 | 5:47 pm